Phosphorylation of Dok1 by Abl family kinases inhibits CrkI transforming activity

[1]  R. Larson,et al.  Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib. , 2014, Blood.

[2]  E. Raymond,et al.  MEK in cancer and cancer therapy. , 2014, Pharmacology & therapeutics.

[3]  Tony Pawson,et al.  Molecular mechanisms of SH2- and PTB-domain-containing proteins in receptor tyrosine kinase signaling. , 2013, Cold Spring Harbor perspectives in biology.

[4]  Renate Griffith,et al.  Therapeutic targeting of c-KIT in cancer , 2013, Expert opinion on investigational drugs.

[5]  J. Condeelis,et al.  Arg/Abl2 promotes invasion and attenuates proliferation of breast cancer in vivo , 2012, Oncogene.

[6]  Z. Herceg,et al.  Inactivation of the putative suppressor gene DOK1 by promoter hypermethylation in primary human cancers , 2012, International journal of cancer.

[7]  Morag Park,et al.  Models of crk adaptor proteins in cancer. , 2012, Genes & cancer.

[8]  P. Reichardt,et al.  Molecular targeted therapy of gastrointestinal stromal tumors. , 2011, Current cancer drug targets.

[9]  Z. Herceg,et al.  Aberrant DNA methylation distinguishes hepatocellular carcinoma associated with HBV and HCV infection and alcohol intake. , 2011, Journal of hepatology.

[10]  R. Birge,et al.  Emerging roles for crk in human cancer. , 2010, Genes & cancer.

[11]  B. Mayer,et al.  Proteins that bind the Src homology 3 domain of CrkI have distinct roles in Crk transformation , 2010, Oncogene.

[12]  H. Nakauchi,et al.  Mice lacking Dok-1, Dok-2, and Dok-3 succumb to aggressive histiocytic sarcoma , 2010, Laboratory Investigation.

[13]  K. Hahn,et al.  Biosensors for Characterizing the Dynamics of Rho Family GTPases in Living Cells , 2010, Current protocols in cell biology.

[14]  W. Gerald,et al.  Identification of DOK genes as lung tumor suppressors , 2010, Nature Genetics.

[15]  William P Schiemann,et al.  Activated Abl kinase inhibits oncogenic transforming growth factor‐β signaling and tumorigenesis in mammary tumors , 2009, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[16]  Y. Yamanashi,et al.  The roles of Dok family adapters in immunoreceptor signaling , 2009, Immunological reviews.

[17]  A. Barclay,et al.  Essential Roles for Dok2 and RasGAP in CD200 Receptor-Mediated Regulation of Human Myeloid Cells1 , 2009, The Journal of Immunology.

[18]  S. Feller,et al.  Crk adaptor protein-induced phosphorylation of Gab1 on tyrosine 307 via Src is important for organization of focal adhesions and enhanced cell migration , 2009, Cell Research.

[19]  M. Basson,et al.  Pressure activates colon cancer cell adhesion via paxillin phosphorylation, Crk, Cas, and Rac1 , 2008, Cellular and Molecular Life Sciences.

[20]  J. Condeelis,et al.  The distinct roles of Ras and Rac in PI 3-kinase-dependent protrusion during EGF-stimulated cell migration , 2007, Journal of Cell Science.

[21]  Tony Pawson,et al.  High-throughput phosphotyrosine profiling using SH2 domains. , 2007, Molecules and Cells.

[22]  M. Osawa,et al.  Dok-1 and Dok-2 are negative regulators of T cell receptor signaling. , 2007, International immunology.

[23]  Elena B. Pasquale,et al.  The EphB4 receptor suppresses breast cancer cell tumorigenicity through an Abl–Crk pathway , 2006, Nature Cell Biology.

[24]  N. Mochizuki,et al.  Involvement of adaptor protein Crk in malignant feature of human ovarian cancer cell line MCAS , 2006, Oncogene.

[25]  K. Hahn,et al.  Spatiotemporal dynamics of RhoA activity in migrating cells , 2006, Nature.

[26]  A. B. Lyons,et al.  In vitro sensitivity to imatinib-induced inhibition of ABL kinase activity is predictive of molecular response in patients with de novo CML. , 2005, Blood.

[27]  Morag Park,et al.  CrkI and CrkII Function as Key Signaling Integrators for Migration and Invasion of Cancer Cells , 2005, Molecular Cancer Research.

[28]  P. Pandolfi,et al.  Role of Dok-1 and Dok-2 in Leukemia Suppression , 2004, The Journal of experimental medicine.

[29]  A. Iwama,et al.  Role of Dok-1 and Dok-2 in Myeloid Homeostasis and Suppression of Leukemia , 2004, The Journal of experimental medicine.

[30]  P. Pandolfi,et al.  Critical role of Dok-1 and Dok-2 in leukemia suppression , 2004 .

[31]  R. Klemke,et al.  Regulation of integrin-mediated cellular responses through assembly of a CAS/Crk scaffold. , 2004, Biochimica et biophysica acta.

[32]  Y. Yamanashi,et al.  Dok‐1 tyrosine residues at 336 and 340 are essential for the negative regulation of Ras‐Erk signalling, but dispensable for rasGAP‐binding , 2004, Genes to cells : devoted to molecular & cellular mechanisms.

[33]  Cem Akin,et al.  A novel form of mastocytosis associated with a transmembrane c-kit mutation and response to imatinib. , 2004, Blood.

[34]  C. Galmarini,et al.  Frameshift mutation in the Dok1 gene in chronic lymphocytic leukemia , 2004, Oncogene.

[35]  David E. Misek,et al.  Increased C-CRK proto-oncogene expression is associated with an aggressive phenotype in lung adenocarcinomas , 2003, Oncogene.

[36]  R. Klemke,et al.  Cytoplasmic c-Abl provides a molecular ‘Rheostat’ controlling carcinoma cell survival and invasion , 2003, Oncogene.

[37]  T. Pawson,et al.  Transgenic RNA interference in ES cell–derived embryos recapitulates a genetic null phenotype , 2003, Nature Biotechnology.

[38]  Peter Marynen,et al.  A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. , 2003, The New England journal of medicine.

[39]  Kenneth M. Yamada,et al.  CrkI adapter protein modulates cell migration and invasion in glioblastoma. , 2003, Cancer research.

[40]  B. Bain,et al.  Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta. , 2002, The New England journal of medicine.

[41]  W. Kabsch,et al.  The Ras-Byr2RBD complex: structural basis for Ras effector recognition in yeast. , 2001, Structure.

[42]  A. Miyawaki,et al.  Spatio-temporal images of growth-factor-induced activation of Ras and Rap1 , 2001, Nature.

[43]  R. Klemke,et al.  Inhibition of Cell Migration by Abl Family Tyrosine Kinases through Uncoupling of Crk-CAS Complexes* , 2001, The Journal of Biological Chemistry.

[44]  D. Baltimore,et al.  Domain-dependent Function of the rasGAP-binding Protein p62Dok in Cell Signaling* , 2001, The Journal of Biological Chemistry.

[45]  H. Hanafusa,et al.  v-Crk activates the phosphoinositide 3-kinase/AKT pathway in transformation. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[46]  D. Baltimore,et al.  Role of the rasGAP-associated docking protein p62(dok) in negative regulation of B cell receptor-mediated signaling. , 2000, Genes & development.

[47]  K. Nelms,et al.  Dok1 encoding p62(dok) maps to mouse chromosome 6 and human chromosome 2 in a region of translocation in chronic lymphocytic leukemia. , 1998, Genomics.

[48]  C. Sawyers,et al.  Structural Requirements for Function of the Crkl Adapter Protein in Fibroblasts and Hematopoietic Cells , 1998, Molecular and Cellular Biology.

[49]  N. Heisterkamp,et al.  Tyrosine 207 in CRKL is the BCR/ABL phosphorylation site , 1997, Oncogene.

[50]  D. Baltimore,et al.  Identification of the Abl- and rasGAP-Associated 62 kDa Protein as a Docking Protein, Dok , 1997, Cell.

[51]  R. Kobayashi,et al.  p62 dok : A Constitutively Tyrosine-Phosphorylated, GAP-Associated Protein in Chronic Myelogenous Leukemia Progenitor Cells , 1997, Cell.

[52]  H. Greulich,et al.  A role for Ras in v-Crk transformation. , 1996, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[53]  S. Feller,et al.  Proline-rich sequences mediate the interaction of the Arg protein tyrosine kinase with Crk. , 1996, Oncogene.

[54]  M. Shibuya,et al.  DOCK180, a major CRK-binding protein, alters cell morphology upon translocation to the cell membrane , 1996, Molecular and cellular biology.

[55]  S. Feller,et al.  Four proline-rich sequences of the guanine-nucleotide exchange factor C3G bind with unique specificity to the first Src homology 3 domain of Crk. , 1994, The Journal of biological chemistry.

[56]  M. Matsuda,et al.  CRK protein binds to two guanine nucleotide-releasing proteins for the Ras family and modulates nerve growth factor-induced activation of Ras in PC12 cells , 1994, Molecular and cellular biology.

[57]  S. Ogawa,et al.  A novel signaling molecule, p130, forms stable complexes in vivo with v‐Crk and v‐Src in a tyrosine phosphorylation‐dependent manner. , 1994, The EMBO journal.

[58]  S. Feller,et al.  c‐Abl kinase regulates the protein binding activity of c‐Crk. , 1994, The EMBO journal.

[59]  M. Shibuya,et al.  C3G, a guanine nucleotide-releasing protein expressed ubiquitously, binds to the Src homology 3 domains of CRK and GRB2/ASH proteins. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[60]  D. Baltimore,et al.  Abl protein-tyrosine kinase selects the Crk adapter as a substrate using SH3-binding sites. , 1994, Genes & development.

[61]  N. Heisterkamp,et al.  Isolation and chromosomal localization of CRKL, a human crk-like gene. , 1993, Oncogene.

[62]  L. Cantley,et al.  Identification and characterization of a high-affinity interaction between v-Crk and tyrosine-phosphorylated paxillin in CT10-transformed fibroblasts , 1993, Molecular and cellular biology.

[63]  T. Pawson,et al.  SH2 domains recognize specific phosphopeptide sequences , 1993, Cell.

[64]  M. Shibuya,et al.  Two species of human CRK cDNA encode proteins with distinct biological activities , 1992, Molecular and cellular biology.

[65]  B. Mayer,et al.  The product of the cellular crk gene consists primarily of SH2 and SH3 regions. , 1992, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[66]  B. Mayer,et al.  Mutagenic analysis of the v-crk oncogene: requirement for SH2 and SH3 domains and correlation between increased cellular phosphotyrosine and transformation , 1990, Journal of virology.

[67]  B. Mayer,et al.  A novel viral oncogene with structural similarity to phospholipase C , 1988, Nature.

[68]  G. Daley,et al.  The chronic myelogenous leukemia-specific P210 protein is the product of the bcr/abl hybrid gene. , 1986, Science.

[69]  H. Abelson,et al.  Lymphosarcoma: virus-induced thymic-independent disease in mice. , 1970, Cancer research.